• Immunovant Inc IMVT.OQ reported a quarterly adjusted loss of 74 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -45 cents. The mean expectation of fourteen analysts for the quarter was for a loss of 60 cents per share. Wall Street expected results to range from -67 cents to -46 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Immunovant Inc's reported EPS for the quarter was a loss of 74 cents​.

• The company reported a quarterly loss of $109.12 million.

• Immunovant Inc shares had risen by 10.2% this quarter and lost 25.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 0.5% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Immunovant Inc is 49.00

This summary was machine generated from LSEG data November 7 at 02:41 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)